Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer

Autor: Mona Abdel-Rahim, Ahmed A. Shokeir, Amira Awadalla, Taeeun D. Park, Muhammad Shahid, Mahmoud Laymon, Eunho Cho, Mohammed Sultan, Jayoung Kim, Ahmed M. Mansour, Mamdouh Elsherbeeny, Ahmed Mosbah, Vikram Sairam, Hassan Abol-Enein
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Nephrology
Male
Survival
medicine.medical_treatment
lcsh:RC870-923
0302 clinical medicine
Epidermal growth factor
Medicine
Epidermal growth factor receptor
Cells
Cultured
Muscle Neoplasms
biology
Bladder cancer
General Medicine
Middle Aged
3. Good health
ErbB Receptors
Gene Expression Regulation
Neoplastic
030220 oncology & carcinogenesis
Immunohistochemistry
Female
Adjuvant
medicine.drug
Research Article
medicine.medical_specialty
Cell Survival
Urology
EGFR
Cystectomy
03 medical and health sciences
Predictive Value of Tests
Internal medicine
Humans
Neoplasm Invasiveness
Cisplatin
Epidermal Growth Factor
business.industry
medicine.disease
lcsh:Diseases of the genitourinary system. Urology
Adjuvant chemotherapy
030104 developmental biology
Reproductive Medicine
Urinary Bladder Neoplasms
Drug Resistance
Neoplasm
biology.protein
business
Follow-Up Studies
Zdroj: BMC Urology, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Urology
ISSN: 1471-2490
DOI: 10.1186/s12894-018-0413-9
Popis: Background Epidermal growth factor receptor (EGFR) overexpression is believed to be associated with bladder cancer (BC) progression and poor clinical outcomes. In vivo studies have linked EGFR subcellular trafficking and chemo-resistance to cisplatin-based chemotherapies. This has not been studied in the clinical adjuvant setting. We aimed to investigate the prognostic significance of EGFR expression in patients receiving cisplatin-based adjuvant chemotherapy following radical cystectomy for advanced BC. Methods The database from the Urology and Nephrology Center at Mansoura University was reviewed. BC patients who were treated with radical cystectomy and adjuvant chemotherapy for adverse pathological features or node positive disease were identified. Patients who underwent palliative cystectomy, had histological diagnoses other than pure urothelial carcinoma, or received adjuvant radiotherapy were excluded from the study. Immunohistochemical staining for EGFR expression was performed on archived bladder specimens. The following in vitro functional analyses were performed to study the relationship of EGFR expression and chemoresponse. Results The study included 58 patients, among which the mean age was 57 years old. Majority of patients had node positive disease (n = 53, 91%). Mean follow up was 26.61 months. EGFR was overexpressed in 25 cystectomy specimens (43%). Kaplan-Meier analysis revealed that EGFR over-expression significantly correlated with disease recurrence (p = 0.021). Cox proportional hazard modeling identified EGFR overexpression as an independent predictor for disease recurrence (p = 0.04). Furthermore, in vitro experiments demonstrated that inhibition of EGFR may sensitize cellular responses to cisplatin. Conclusions Our findings suggest that EGFR overexpression is associated with disease recurrence following adjuvant chemotherapy for advanced BC. This may aid in patient prognostication and selection prior to chemotherapeutic treatment for BC.
Databáze: OpenAIRE
Externí odkaz: